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Background: Microvesicles (MV) havebeen implicated in the development of thrombotic disease, such as acute
respiratorydistresssyndrome(ARDS)andmultipleorganfailure(MOF).Traumapatients areatincreasedrisk
oflatethrombotic events, particularlythosewhoreceivea major transfusion. Theaims ofthisstudy were:(a)to
determine whether there were increased numbers of pro-coagulant MV following injury; (b) to determine their
cellular origin; and (c) to explore the effects of MV with clinical outcomes; in particular red cell transfusion
requirements and death.
Methods: Trauma patients were recruited at a Level 1 trauma centre. The presence of MV procoagulant
phospholipid (PPL) was assessed using 2 activity assays (PPL and thrombin generation). Enumeration and
MV cellular origin was assessed using 2 colour flow cytometry.
Results: Fifty consecutive patients were recruited; median age 38 (IQR: 24 55), median ISS 18 (IQR: 9 27).
Circulating procoagulant MV, rich in phospholipid, were significantly elevated following traumatic injury
relative to controls and remained elevated at 72 h post-injury. Red cell/AnnV  and platelet/AnnV  MV
numbers were 6-fold and 2-fold higher than controls, respectively. Patients who died (n 9, 18%) had
significantly fewer CD41/AnnV  MV and lower endogenous thrombin potential relative to patients who
survived.
Conclusions: MV are elevated following traumatic injury and may be implicated in the increased risk of
trauma patients to pro-thrombotic states such as MOF and ARDS. Lower levels of procoagulant MV are
associated with mortality and further investigation of this association is warranted.
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T
hrombosis-related morbidity rates are high follow-
ing traumatic injury particularly in patients who
survive major haemorrhage (1 4). Pathophysiolo-
gical changes that lead to the pro-thrombotic state after
injury are incompletely understood. Inflammatory med-
iators, cytokines and microvesicles (MV) are known to
be produced and released in large quantities following
major trauma, which may contribute to a dysfunctional,
exaggerated pro-thrombotic inflammatory response and
risks of adverse clinical outcomes including secondary
organ damage associated with acute respiratory distress
syndrome (ARDS) and multiple organ failure (MOF) (2),
both of which have a high prevalence in trauma survi-
vors (5). Almost a third of severely injured patients
develop MOF (4) and in those patients who receive
a major transfusion (]6 Units RBC), 50% go on to
develop ARDS (3).
MV have been shown to play a role in the development
of venous thromboembolism (VTE), MOF and ARDS
(5 7). MV are small (100 nm 1 mM), extracellular
vesicles, released from a range of cell types following cellu-
lar activation and injury, and possess cell markers that are
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(page number not for citation purpose)characteristic of their cell of origin (8). MVoften express
anionic phospholipids which can activate and support
coagulation and thus promote thrombosis. Some types
of MV (mostly those of monocytic or tumour origin)
have exposed tissue factor (TF) on their surfaces, which
can activate the clotting cascade and increase the risk of
thrombosis (8).
The overall objective of this pilot study was to char-
acterisethechangesinMVduringtrauma.Theaimsofthis
work were: (a) to determine whether there were increased
numbers of MV in the plasma of patients following injury
and to determine their cellular origin; (b) to ascertain
whethertheMVwerepro-coagulantinnature,dueeitherto
the presence of phospholipid or TF and (c) to explore the
effects of MV with clinical outcomes; in particular red cell
transfusion requirements and death.
Materials and methods
Patient selection
This was a sub-study of a larger prospective observational
study (Activation of Coagulation and Inflammation after
Trauma, ACIT) of consecutive traumapatients presenting
directly to a Level 1 trauma centre. All adult trauma
patients (16 years and over) who met the local criteria for
trauma team activation were eligible for enrolment.
Exclusion criteria were: arrival in the emergency depart-
ment (ED) more than 2 h following injury, administration
of more than 2,000 mL intravenous fluid prior to hospital
arrival, transfer from another hospital, and burns of more
than 5% total body surface area. Patients were retro-
spectively excluded if they: declined togive consent for the
research study, were receiving anticoagulant medications
(not including aspirin), or had moderate or severe liver
disease or a known bleeding diathesis. Emergency consent
was obtained from the trauma team leader (a physician
independent of the research study), who acted as the
patient’s legally authorised representative. Written con-
sent from the patient or next of kin was obtained as soon
after enrolment as appropriate. Twenty healthy, age and
gender matched, volunteers were used as a control group.
The study was reviewed and approved by the National
Research Ethics Committee.
Sampling technique
Blood was drawn from the antecubital fossa or femo-
ral vein (trauma participants) or antecubital fossa only
(healthyvolunteers)withminimalstasisandatleasta5mL
discard. Blood draw from trauma participants was per-
formed within 20 min of arrival to the ED. The blood for
MVanalysis was drawn into two 2.7 mL citrated Vacutai-
ner tubes (0.109 M buffered sodium citrate, 3.2% (w/v)
Becton Dickinson, Plymouth, UK) and processed in the
trauma research laboratory. Blood samples were also
drawn at 72 h (912 h) from admission for trauma
participants. Samples were drawn at 1 time point only for
the healthy control group. All samples were transported
to the laboratory with minimal agitation andwere processed
within 1h of collection (9).
Pre-analytical sample handling was conducted as care-
fully as the clinical situation allowed and samples from
the healthy controls were handled identically to trauma
patients, to enable direct comparisons to be made bet-
ween groups (9,10). Samples were subjected to a double
centrifugation step; 2,000 g at 208C for 20 min followed by
13,000 g at 208C for 2 min (11,12). The resulting platelet
free plasma was immediately frozen in 500 mL Eppendorf
tubes at  808C until batch analysis. Storage for controls
and subjects samples was of similar duration and sam-
ples were analysed within 6 months of collection (10).
All samples were defrosted at 378C in a water bath and
analysis followed the methods set out below. None of the
patients or controls were receiving thrombin inhibitors
or treatment doses of low molecular weight heparin.
Sample analysis
The presence of MV procoagulant phospholipid was as-
sessed using 2 activity assays (PPL and thrombin genera-
tion) and validated by flow cytometry. The presence of
TF was assessed using the thrombin generation assay
and validated by flow cytometry. Enumeration and cellu-
lar origin of the MV was assessed using 2 colour flow
cytometry.
PPL assay
This is an automated clotting activity assay (STA†-
Procoag-PPL, Stago, Asnieres, France) in which the meas-
ured clotting time is dependent on the quantity of PPL
present in the test plasma. Exogenous PPL accelerates
the activation of prothrombin by Factor Xa, therefore, the
more PPL present in a plasma sample, the shorter the
clotting time. 25 mL of test plasma was added to 25 mL
of manufactured citrated human plasma, from which
PPLs had been removed, and incubated at 378C. 100 mL
of a CaCl2 and bovine Factor Xa mix was added as an
automated step and the time to fibrin formation was
measured by the STA-R† evolution (Stago, Asnieres,
France). All samples were tested in duplicate. Test assay
controls (P-PPL Controls N and P) were performed accord-
ing to the manufacturer’s instructions (Stago Diagnostica,
France).
CAT assay
Thrombingenerationassayswereperformedontheplasma
samples using 2 different reagents; PRP reagent and MP
(microparticle)reagent.Thrombingenerationwasassessed
by calibrated automated thrombography (CAT) as pre-
viously described (13). 80 mL of platelet poor plasma from
each trauma patient or healthy control was dispensed
into the wells of round-bottom polypropylene 96-well
microtitreplates.20mLofeitheraPRPreagentcontaining
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Thrombinoscope, BV) or a MP reagent containing no TF
and 4 mM phospholipid (a mixture of phosphatidylserine,
phosphatidylethanolamineandphosphatidylcholine)(MP
reagent, TS60, Thrombinoscope, BV), used to initiate
thrombin generation, was added to the plasma samples.
20mLFLUCAreagent(Flucakit,TS50,Thrombinoscope,
BV), containing fluorogenic substrate and CaCl2 were
automatically dispensed by the fluorometer into each
welltotriggerthrombingeneration.Fluorescencewascon-
tinuouslymonitoredwithaFluoroscanAscentplatereader
(Thermo Labsystems, Helsinki, Finland) and a dedicated
programme, Thrombinoscope†, was used to calculate
thrombin activity against a Thrombin Calibrator (TS30,
Thrombinoscope, BV) and display thrombin activity
versus time. The fluorescence filters used were an ex-
citation filter of 390 nm and an emission filter of 460 nm,
as supplied by Thrombinoscope BV. Four parameters
were derived from the thrombograms: lag-time, time to
peak, peak thrombin activity, and area under the curve  
the endogenous thrombin potential (ETP) (13).
Flow cytometry
AllassayswereperformedonaBDLSR-IIflowcytometer
(BD Biosciences, Oxford, UK) and analysed at high flow
rate with an aperture of 50 microns. Photomultiplier
tube gain/voltage settingsand instrument thresholds were
optimised for gating on MV using Megamix fluorescent
beads (Biocytex, Marseille, France) (9). Fluorescent la-
belled monoclonal antibodies (Beckman-Coulter and
BD Pharmingen) were selected to establish the cellular
origin of the MV. The antibodies selectedwere against pan
leucocyte (CD45 ), monocyte (CD14 ), platelet GPIIb
(CD41 ), TF (CD142 ), and red cell glycophorin
A (CD235a ) surface markers. To differentiate between
platelets and endothelial cells, a combination of CD31
and CD41 was used (i.e. endothelial cells were CD31
positive, CD41 negative) (14,15). To establish procoagu-
lant properties of the MV, a dual labelling procedure was
used, where by the MV were additionally labelled with
either annexin V (BD Biosciences, Cowley, UK) (16) or
CD142  (BD Biosciences) to detect expression of phos-
pholipid or TF, respectively (see Table I). The CD142 
solutionwascentrifugedpriortouse(at12,000gfor2min)
and the resulting supernatant used, to remove antibody
aggregates from the monoclonal antibody solution (17).
No other antibodies contained significant levels of anti-
body aggregates.
For each sample, 50 mL of test plasma was stained with
5 mL fluorochrome-labelled monoclonal antibody or re-
spective isotype control. Isoton flow sheath fluid (40 mL)
was then added and the tube incubated at room tempera-
ture for 10 min (14). Samples were then diluted with a
further 900 mL Isoton flow sheath fluid. 950 mL of this
suspension was transferred to a Trucount† beadtube (BD
Biosciences). For those samples labelled with annexin
V-FITC, HBS-Ca (NaCl 0.145 mmol/L, KCl 5mmol/L,
MgSO4 1 mmol/L, HEPES 10 mmol/L, pH 7.4) was used
as the diluent containing either 2.5 mmol/L CaCl2 or K2
EDTA-HBS (5 mmol/L, K2 EDTA in HBS) in the con-
trol tubes. Where HBS-Ca was used, Gly Pro Arg Pro
amide (Sigma-Aldrich, Poole, UK) was used to prevent
clot formation (18), and the volume of diluent adjusted
accordingly. All sampleswere subsequently evaluatedwith
compensation made to control for fluorescence crosstalk
of the emission spectra of fluorescein isothiocyanate and
phycoerythrin in single labelling experiments. Trucount†
beads (BD Biosciences) facilitated the accurate calcu-
lation of MV absolute numbers, using the following
formula:
Absolute count of cell population ¼
Number of events in quadrant Total number of
containing cell population
Number of events in absolute
 
beads per test
 
Test volume
count bead region
Isotype controls were performed to validate all test
results, where a B2% cut-off was used andwas similar for
all controls. In addition to measuring the MV using a
forward scatter trigger, 10 volunteer and 10 patient sam-
ples were analysed using an alternative analysis method
using a fluorescence threshold or trigger alone to evaluate
the effects of a scatter threshold and Megamix gating on
microvesicle detection (19).
Filtration analysis
To demonstrate the particulate nature of the MV, a small
number of samples were analysed pre- and post-single
filtration step. Five trauma samples and 5 healthy vol-
unteer samples were tested using the PPL and thrombin
generation assays and were then subjected to filtration
using a 0.2 mm filter (Ceveron† MFU-500, Technoclone,
Dorking, UK). The freshly prepared filtered aliquotswere
then re-analysed to study the impact of the removal of the
MV by this procedure (14).
*Provided by manufacturer.
Table I. Monoclonal antibody markers
Monoclonal Ab markers Cell derived MV detected
CD41 /AnnV  Procoagulant-positive platelet
CD235a /AnnV  Procoagulant-positive red cell
CD31 /CD41  Endothelial cell
CD14 /CD142  TF-positive monocyte
CD41 /CD142  TF-positive platelet
CD45 /CD142  TF-positive leucocyte
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Data were collected prospectively on patient demo-
graphics, time of injury, mechanism of injury (blunt or
penetrating), pre-hospital fluid administration, time of
arrival to ED, and admission vital signs. Blood transfu-
sion requirements were collected prospectively for each
patient. Venous thromboembolic events (deep venous
thrombosis and pulmonary embolism), organ failure
data   that is, single organ failure, ARDS and MOF
data were prospectively collected to day 28.
Outcome measures
Patients were followed until hospital discharge or death.
Outcome measures recorded were 28 day mortality, red
cell transfusion requirements, single organ failure, ARDS
and MOF. ARDS was defined according to the Berlin
consensus definition (20) and organ failure was defined
as a SOFA score of  2 for any of the 6 organs/systems
evaluated, and MOF as more than 1 failing organ (21).
Statistical analysis
Data were analysed using EXCEL 2003 (Microsoft Inc.,
Redmond, WA, USA) and SPSS (IBM Statistical Package
for Social Sciences, version 20, Chicago, Illinois). All data
were tested for normality. Normally distributed data were
described using mean and standard deviation (SD), and
non-parametric data were described using median and
interquartile range (IQR). Parametric data were com-
pared using a Student’s t-test (unpaired, 2 tails) test and
non-parametric data using a Mann Whitney U test or
Wilcoxon test as appropriate. Reference ranges were
determined according to standard guidelines for PPL an-
alysis, calculating the range as 1.96 SD from the mean.
A p-value of B0.05 was chosen to represent statistical
significance throughout, unless otherwise stated.
Results
Fifty consecutive patients were recruited over a 10 month
period intothe ACITstudyat the John Radcliffe Hospital,
Oxford, UK. No patients were excluded and all patients,
or their next of kin, provided written informed consent.
Fifty trauma samples were available for analysis at time
0 h but fewer samples were available for testing at time
72 h (n 30) as a result of: death (n 6), patients being
discharged home (n 4) or patients declining blood
samples (n 10). Median time from injury (estimated as
the time from when the emergency services were alerted)
to blood sampling was 64 min (IQR: 50 85 min). The
demographics and injury characteristics of all patients are
shown in Table II. No patient developed a VTE, 4 patients
(8%) developed ARDS and 3 (6%) developed single organ
failure, whilst 4 (8%) patients developed MOF. Three out
of the 4 patients with MOF also had ARDS.
Twenty healthy volunteers formed the control group;
median age 38 (IQR: 31 48) and 60% were male. Results
for the control group conformed to normality (unless
otherwise stated) and all results for the trauma patients’
violated normality (Kolmogorov Smirnov and Shapiro 
Wilks tests).
PPL analysis
PPLclotting timesweresignificantlyshorterin thetrauma
group; median value 51.1 sec at time 0 h (IQR: 36.1 55.5
sec) and 64.2 sec at time 72 h (IQR: 55.7 70.6 sec), when
compared with the control group, median 82.9 sec (IQR:
71.1 88.8 sec); pB0.001 for both time points (Mann 
Whitney U, 2 tailed) (see Fig 1). 80% and 33% of trauma
patients’ results were shorter than the local normal range
(datanotshown),foradmissionandtime72h,respectively.
Comparison between the 2 time points for trauma de-
monstrated significantly shorter PPL times at admission
than at 72 h (pB0.001, Wilcoxon signed rank).
CAT results
PRP reagent
All 4 CAT parameters for trauma patients at time 0 h
were found to be significant relative to the control group
Table II. Clinical characteristics of trauma patients
Patients
Number 50
Age 38 (24 55)
Male 31 (62%)
Time (min)
Injury to ED arrival 73 (57 91)
ED arrival to sample 6 (2 9)
Injuries
Injury severity score 18 (9 27)
ISS 0 4 2 (4%)
ISS 5 15 20 (40%)
ISS 16 30 21 (42%)
ISS 31  7 (14%)
Penetrating injury 1 (2%)
Admission physiology
SBPB100 mmHg 8 (16%)
Base deficit 6 mEq/L 5 (10%)
PT (sec) 13.5 (12.9 14.9)
PT ratio 1.2 4 (8%)
CA5 EXTEMB36 mm 13 (26%)
Transfusion requirements (first 12 h)
Any RBC units 13 (26%)
RBC]10 units 4 (8%)
FFP 5 (10%)
Platelets 5 (10%)
Cryoprecipitate 2 (4%)
Outcome measures (day 28)
Patients died 9 (18%)
Patients with VTE (PE/DVT) 0 (0%)
Patients with ARDS and/or organ failure 8 (16%)
Values are median (interquartile range) or number of patients (%).
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(see Table III), indicating that thrombin generation was
higher (64% of participants had an ETP higher than the
normal range) and occurred more quickly in the trauma
group. Comparison between the 2 time points for the
trauma patients corroborated the PPL results; all CAT
parameters were significant (ETP: p 0.02; lagtime, peak
and ttPeak: p50.001) with time 0 h results being over-
all faster and having higher thrombin production. Peak
thrombin production and ETP correlated highly with
PPL times; r  0.80 and  0.56, respectively (p50.001,
Spearman rho).
MP reagent
Three CAT parameters at time 0 h were found to be
significant relative to thecontrol group (p50.001 for ETP
and peak thrombin; p 0.04 for lagtime) (see Table IV),
with results that suggested that overall thrombin genera-
tion was lower but occurred more quickly in the trauma
group. Time 72 h results were mixed when compared to
the controls. Only 1 parameter, peak thrombin, was
significantly higher than the control group (p 0.01).
Overall, ETP was not significantly greater (p 0.5) than
controls. Comparison between the 2 time points for the
trauma patients revealed significantly different results
Fig. 1. Procoagulant phospholipid measurements using the PPL assay: comparison of 2 time points following injury. Box plots (median
and IQR) depicting average PPL results in trauma participants at 2 time points (time 0 and 72 h), when compared to a healthy control
group. The PPL assays were signiﬁcantly shorter (pB0.001) at both time points in the trauma cohort when compared to the control.
Time 0 h trauma samples were signiﬁcantly shorter than the results at time 72 h (pB0.001), suggesting more procoagulant MV early
after injury.
Table III. Thrombin generation data: PRP reagent
Trauma time 0 h Trauma time 72 h Controls
Sample Median IQR Median IQR Median IQR
Lagtime (min) 5.9* 4.8 6.3 9.0 8.3 10.0 6.7 6.1 7.3
ttPeak (min) 10.8* 9.1 12.5 16.6* 14.9 17.7 14.9 13.6 15.6
Peak thrombin (nM) 160* 124 199 68 50 85 58 43 67
ETP (nM) 1,671* 1,421 1,968 1,335* 1,199 1,554 918 790 1,205
This table depicts data for thrombin generation using PRP reagent. Data for the trauma cohort (at time 0 and time 72 h) were compared
with a control group   all significant results (pB0.05) are marked with an *. All 4 CAT parameters at time 0 h were significant relative to the
control group (p50.001 for all parameters, except lagtime; p 0.003), indicating thrombin generation was greater and occurred more
rapidly in the trauma group. Comparison between the 2 time points showed significant differences (ETP: p 0.02; lagtime, peak and
ttPeak: p50.001) with time 0 h results being overall faster and having higher thrombin production.
Microvesicle provenance following trauma
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Filtration results
Five trauma patients and 5 volunteers were analysed and
these groups were representative of the each group as a
whole. Significant prolongation of PPL times (p 0.04,
Wilcoxon signed rank) occurred following filtration in
trauma samples, with the average PPL time increasing by
48%. CAT results were consistent; a significant reduction
in thrombin generation was seen (p 0.04). ETP and
peak thrombin values fell by 62 and 78%, respectively.
Filtration of control samples led to similar changes.
These results suggest that particulate matter which is
actively involved in coagulation is removed by filtration.
Flow cytometry
Trauma patients had significantly increased total num-
bers of Annexin V positive (AnnV ) MV relative to
controls (p 0.001) (see Table V), and this included a
2-fold increase in those MV identified as platelet/AnnV 
(p 0.02) and a 6-fold increase in those MV identified as
RBC/AnnV  (p50.001) particles. The highest number
of MV were found to label solely for AnnV  and these
were 2-fold higher in the trauma group relative to con-
trols (p 0.01). Numbers of endothelial cells and leuco-
cyte/TF marked cells did not differ significantly from the
control group (p 0.1), but there were higher absolute
numbers of monocyte/TF and platelet/TF MV in trauma
patients.
In order to assess whether trauma per se affected the
relative proportions of MV subtypes, the percentage of
each MV subtype was calculated for individual trauma
patients as well as control subjects, and these data were
compared using non-parametric tests (Table V). Signifi-
cant differences were only noted in 2 MV subtypes:
procoagulant red cells (CD235a /AV ) and endothelial
cells (CD31 /41 ). There was a greater proportion
of CD235a /AV  MV (p 0.02, Mann Whitney U,
2 tailed) and a lower proportion of CD31 /41  MV
Table IV. Thrombin generation data: microparticle reagent
Trauma time 0 h Trauma time 72 h Controls
Sample Median IQR Median IQR Median IQR
Lagtime (min) 8.8* 7.5 10.7 10.0 9.0 11.2 11.3 10.0 12.9
ttPeak (min) 11.0* 9.8 13.2 11.9* 11.1 13.5 13.3 11.7 15.0
Peak thrombin (nM) 282* 239 342 369 329 433 429 384 493
ETP (nM) 1,147* 967 1,266 1,827 1,593 2,067 1,741 1,551 1,974
This table depicts data for thrombin generation using PRP reagent. Data for the trauma cohort (at time 0 and time 72 h) were compared
with a control group   all significant results (pB0.05) are marked with an*. At time 0 h significantly less thrombin was generated compared
to control (ETP value: p50.001). Overall, ETP was not significantly greater (p 0.5) than controls at time 72 h. Comparison between the
2 time points for the trauma patients revealed significantly different results (Lagtime: p 0.02; ttPeak: p 0.03; ETP and peak: p50.001)
with time 0 h results being overall faster and having higher thrombin production.
Table V. Quantiﬁcation of microvesicle numbers in platelet poor plasma from trauma and control groups using dual labelled ﬂow
cytometry
Trauma time 0 Controls
Sample Median (per mL) IQR % of total MV Median (per mL) IQR % of total MV
% of trauma patients
 95% CI of controls
CD41 /AV  177* 65 456 17 86 65 127 24 60
CD235 /AV  171** 98 290 17
$ 38 26 78 8 67
AnnV  573** 364 941 56 215 128 524 53 61
CD31 /41  16 10 35 2
ˆ 17 9 34 5 18
CD14 /142  30 10 47 3 12 9 36 3 47
CD41 /142  30 9 52 3 13 11 42 4 41
CD45 /142  27 9 48 2 12 8 45 3 8
Key: AnnV   Annexin V; CI   confidence interval. Trauma cohort data at admission are compared with control data. There are significantly
greater numbers of procoagulant MV present (AnnV ;p 50.001) in the trauma samples which are of both platelet and red cell origin
(*denotes pB0.05; **denotes p50.001). When comparing the distribution of MV subtypes, there is a greater proportion of CD235a /
AnnV  MV (
$denotes p 0.02, Mann Whitney U) and a lower proportion of CD31 /41- MV (
ˆdenotes p 0.004, Mann Whitney U) in the
plasma of trauma patients.
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Analysis using a fluorescence threshold delivered near
comparable results, but with higher numbers of MV found
for each cell type. The only result that was in variance
to scatter thresholding, was that a significantly higher
number of endothelial cells were seen in the trauma group
relative to controls (data not shown)
Correlation with clinical outcomes
The PRP ETP result at admission was significantly lower
in patients who died (median 1524.5 per mL; IQR:
1155.5 1551.5) relative to those who survived to day 28
(median 1732.3 per mL; IQR: 1,466 1973.9) (p 0.025,
Mann Whitney U, 2 tailed). In keeping with this finding,
absolute numbers of CD41/Annexin V-positive MV were
significantly lower in trauma patients who died (n 9,
median 40.2 per mL; IQR: 38.6 133.5) compared to
patients who survived (n 41, median 202.1 per mL;
IQR: 93.4 561.7) to day 28 (p 0.015, Mann Whitney U,
2 tailed) (see Fig 2). Survival correlated positively with
CD41/AnnV  MV numbers (p 0.01, r 0.35). Median
plateletcountsweresignificantlylower197 10
 9L(IQR:
145 223) in the cohort of patients that died compared
with 273 10
 9 L (IQR: 223 301) in those that survi-
ved (p 0.004, Mann Whitney U, 2 tailed). The platelet
count and CD41/AnnV  MV numbers did not show
a correlation with each other (r  0.12; p 0.44).
AtrendwasseenbetweennumbersofTF-positiveMVat
admission and numbers of RBC transfused within the
first 24 h of admission; r 0.247, p 0.09 for platelet/TF
microparticles and r 0.248, p 0.05 for monocyte/TF
MV (all TF-positive cells together: r 0.395, p 0.005).
When dividing the trauma group into those who received
noRBCorthosewhoreceivedatleast1unitormoreRBC;
there was a significantly greater number of platelet/TF-
positive MV (median 40.5mL
 1; IQR: 30.2 53.4) in the
groupthatreceivedRBCrelativetothegroupthatreceived
no RBC (median 24.7mL
 1; IQR: 8.9 45.6).
Discussion
This pilot study has characterised and reported on
longitudinal changes in MV formation in trauma. Using
3 complementary laboratory methods, circulating pro-
coagulant MV, rich in phospholipid, were found to be
significantly elevated following traumatic injury relative
to controls and remained elevated at 72 h post injury.
The presence of procoagulant particulate matter was
confirmed by filtration. Red cell/AnnV  and platelet/
AnnV  MV numbers were 6-fold and 2-fold higher than
controls, respectively. Endothelial cell and leucocyte/TF
microvesicle numbers were not elevated following trauma
and although the absolute numbers of monocyte/TF
and platelet/TF MV were higher in the trauma group
compared to controls, significance was not reached.
MV are known to be released following cellular
activation, as well as during vascular shear stress (8,22),
and it was hypothesised that MV numbers would increase
following trauma. All 3 laboratory methods confirmed
that injury caused a significant increase in MVassociated
phospholipid procoagulant activity (as measured by PPL
and CAT PRP assays) and an increase in total numbers
of phospholipid-rich procoagulant MV (as measured by
flow cytometry). There were differences between the dis-
tribution of MV between trauma and control subjects.
Recently published data show similar results with both
elevated procoagulant red cell MV and proportionately
lower platelet MV in the trauma group (23).
A strong relationship was evident between results
from the 2 activity assays, providing intra-study valida-
tion and as further confirmation, there was good cor-
relation between total numbers of AnnV  microvesicles
and PRP ETP (r 0.34; p 0.02) and PRP peak throm-
bin production (r 0.33; p 0.02). These results provide
early evidence that trauma leads to a marked increase in
phospholipid rich red cell and platelet MV that have
procoagulant activity by the time of hospital admission.
These data confirm results from another study to evalu-
ate MV after injury (24), although this study was also
able to demonstrate a relationship between AnnV MV
number and injury severity, which was not evident with
these data.
This study did not demonstrate a significant increase
in TF-positive MV numbers, using either flow cytometry
or CAT, although a small absolute increase in numbers
was seen. The presence of TF on MV has been reported
to be an important risk factor for thrombosis (25). In
health, circulating TF levels are low, and the majority
of TF can be found on MV surfaces (26). Other studies
have reported high plasma TF levels after traumatic in-
jury (27,28). The reasons for these differences are unclear.
There has been no consensus about the most accurate
standard for the measurement of TF-bearing MV (29)
and false-negative results with certain anti-TF mono-
clonal antibodies can occur as shown with HTF-1 the
clone used in this study (30). It is also possible that MV
associated TF due to its low copy number and/or the size
of vesicle measured is below the detection limit of current
flow cytometers (31).
In our study, an activity assay was also used to improve
validity of results. Of interest, however, was the posi-
tive finding that the volume of RBC transfused was asso-
ciatedwith higher TF-rich MV numbers. It is theoretically
possible that those patients with greater vessel damage,
that is, those more likely to bleed also have greater
amounts of exposed subendothelial TF.
Nine trauma patients died in our study. Eight patients
had a pro-thrombotic disorder: ARDS, and/or single or
MOF. None of the patients developed a VTE during their
hospital stay. These small numbers limit interpretation of
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were found with either MV numbers or activity and
outcomes. Of interest, patients who died were found to
have significantly lower numbers of CD41 /AnnV  MV
and lower ETP relative to patients who survived. This
suggests that those patients at greatest risk of death were
those unable to mount a hypercoagulable response to
injury. A recentstudy in trauma confirmed the association
Fig. 2. Association between procoagulant microvesicle number, procoagulant derived thrombin generation and mortality. (a). Numbers
of procoagulant MVof platelet origin (CD41 /AnnV ) in the plasma of samples at admission to hospital from trauma survivors and
non-survivors. There is a signiﬁcantly greater number of platelet derived procoagulant MV in plasma from survivors (n 41,
median 202.1 per mL; IQR: 93.4 561.7) when compared to participants who died (n 9, median 40.2 per mL; IQR: 38.6 133.5)
(p 0.015). Survival correlated positively with CD41/AnnV  MV numbers (p 0.01, r 0.35). (b). Endogenous thrombin potential
values in admission samples from trauma survivors and non-survivors. Box plots of median ETP values (PRP reagent) comparing
survivors with non-survivors. The PRP ETP result at admission was signiﬁcantly lower in patients who died (median 1524.5 per mL;
IQR: 1155.5 1551.5) relative to those who survived to day 28 (median 1732.3 per mL; IQR: 1466 1973.9) (p 0.025).
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and mortality (23). Similar associations between MOF
and/or mortality and MV have been reported in other
studies (32,33). In a small study,Soriano et al. (32)showed
that platelet MV numbers and markers of inflammation
were significantly lower in septic patients with MOF, and
were strong predictors of death.
There are potential limitations to this study, in addition
to sample size. Analysis of MV depends on many pre-
analytical and analytical factors (9) and to minimise
variation this study followed the recommended ISTH
SSCguidanceforstandardisationofMVanalysis.Notably,
however, there were significant differences in numbers of
MVdetecteddependingonthesetupoftheflowcytometer
(using a scatter threshold and instrument parameters/
gating set with polystyrene megamix beads compared to a
fluorescence threshold). The data from this study con-
firm that instrument settings based upon a scatter trigger
and calibration bead gating leads to detection of only
larger MV with loss of detection of smaller MV (19).
A fluorescence threshold therefore enables smaller MV to
be detected (34). Similarly, CAT results are highly depen-
dent on TF quantities and the presence of contact factor
activation (35). The CAT samples were not collected in
corn trypsin inhibitor (which inhibits contact activation)
for pragmatic reasons and this may have had an effect
on the CAT results. The comparison of results between
volunteer and patient groups went some way towards
minimising the importance of this effect.
Conclusions
MVareelevated following traumatic injury, and havebeen
shown in vitro to be procoagulant in nature. These MV
may be implicated in the increased riskof trauma patients
toVTE andother pro-thrombotic statessuch asMOFand
ARDS. Lower levels of procoagulant MV are associated
withmortalityandfurtherinvestigationofthisassociation
iswarrantedasMVlevelsandtransientincreasesfollowing
injury may be an important and normal physiological
response to injury.
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